NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been given a consensus recommendation of “Moderate Buy” by the eleven research firms that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $20.20.

A number of analysts have recently issued reports on NEO shares. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price target on shares of NeoGenomics in a research report on Friday, January 10th. Benchmark lowered shares of NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, January 13th. The Goldman Sachs Group decreased their target price on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Bank of America upped their price target on shares of NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Finally, Jefferies Financial Group assumed coverage on NeoGenomics in a research report on Tuesday, December 10th. They set a “buy” rating and a $22.00 price objective for the company.

NeoGenomics Stock Up 2.2 %

Shares of NeoGenomics stock opened at $13.78 on Thursday. NeoGenomics has a 1 year low of $12.13 and a 1 year high of $19.11. The company has a market cap of $1.77 billion, a P/E ratio of -22.59 and a beta of 1.23. The company has a current ratio of 1.99, a quick ratio of 1.91 and a debt-to-equity ratio of 0.37. The stock has a 50-day moving average price of $15.91 and a 200 day moving average price of $15.64.

Insiders Place Their Bets

In related news, General Counsel Alicia C. Olivo sold 5,175 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $15.36, for a total value of $79,488.00. Following the transaction, the general counsel now directly owns 37,129 shares of the company’s stock, valued at approximately $570,301.44. This trade represents a 12.23 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On NeoGenomics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NEO. SBI Securities Co. Ltd. bought a new stake in shares of NeoGenomics during the 4th quarter worth $26,000. Versant Capital Management Inc lifted its position in shares of NeoGenomics by 174.9% during the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock worth $30,000 after purchasing an additional 1,142 shares during the last quarter. Quarry LP bought a new stake in NeoGenomics during the 3rd quarter valued at approximately $40,000. Blue Trust Inc. grew its holdings in NeoGenomics by 42.3% in the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock valued at $46,000 after buying an additional 987 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its position in NeoGenomics by 203.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company’s stock worth $70,000 after buying an additional 2,787 shares during the period. Institutional investors and hedge funds own 98.50% of the company’s stock.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.